[Renal cell carcinomas. Pathomorphologic diagnosis in the light of modern pharmacotherapy]

Renal carcinomas have been classified with increasing accuracy in recent years and new sub-groups have been assigned, which, due to their distinct development pathways, carry varying prognoses and require specific treatment approaches. A range of antibodies are available for their immunohistochemical classification. Identifying a gene defect--mutation, deletion, trisomies and monosomies, oncogene activation--enables the application of targeted therapy, e.g. using antibodies or tyrosine kinase inhibitors in signaling pathways, among others. Renal carcinoma diagnosis by the pathologist is taking on a particularly important role.